摘要
盐酸米托蒽醌脂质体注射液作为新型蒽环类药物脂质体制剂,目前已被批准用于既往至少经过一线标准治疗的复发或难治外周T细胞淋巴瘤(PTCL)成年患者。盐酸米托蒽醌脂质体注射液属于2.2类改良型新药,于2022年1月7日在中国获批上市,目前其在临床实践中的应用数据有限。为进一步规范盐酸米托蒽醌脂质体注射液在PTCL中的临床应用,专家组成员结合盐酸米托蒽醌脂质体注射液相关临床研究数据,制定了该临床应用指导原则,供临床医生参考。
Mitoxantrone hydrochloride liposome injection,a novel anthracycline liposome preparation,has been approved for treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma(PTCL)after at least one prior standard treatment.Mitoxantrone hydrochloride liposome injection as a class 2.2 modified new drug was approved to be marketed in China on January 7,2022;at present,the data of its clinical practice remain limited.In order to further standardize the clinical application of mitoxantrone hydrochloride liposome injection in PTCL,the members of the expert group work out the guiding principles for clinical application of mitoxantrone hydrochloride liposome injection by combining with the relevant clinical research data to provide references for clinical physicians.
作者
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会
马军
朱军
黄慧强
Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology and Oncology,Harbin 150010)
出处
《白血病．淋巴瘤》
CAS
2022年第5期257-262,共6页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
T细胞
外周
米托蒽醌
脂质体
临床研究
治疗结果
Lymphoma,T-cell,peripheral
Mitoxantrone
Liposomes
Clinical research
Treatment outcome
